Use of a gamma-2 herpesvirus as a vector to deliver antibodies to rhesus monkeys

G. F. Bischof, Y. C. Shin, S. P. Fuchs, J. M. Martinez-Navio, W. A. Lauer, E. G. Rakasz, Ronald Charles Desrosiers

Research output: Contribution to journalArticle

Abstract

The gamma-2 herpesvirus of rhesus monkeys, rhesus monkey rhadinovirus (RRV), persists principally in B cells of its host. We constructed recombinant strains of RRV expressing the rhesus monkey-derived anti-SIV monoclonal antibodies 4L6 and 5L7 and compared the RRV-mediated in vivo delivery of these antibodies in rhesus monkeys with previous studies that utilized intramuscular delivery with an adeno-associated virus (AAV) vector. Recombinant RRV-4L6 and RRV-5L7 were both shown to stably produce the antibodies in persistently infected B-cell lines in culture. Two RRV-negative rhesus monkeys were experimentally infected with recombinant RRV-4L6 and two with recombinant RRV-5L7. Following infection, the appearance of the delivered antibody was readily detected in all four animals. However, the levels of the delivered antibody were considerably lower than what has been typically observed following intramuscular AAV delivery. Furthermore, three of the four monkeys had an antibody response to the delivered antibody as had been observed previously with intramuscular AAV delivery of these same antibodies. We conclude that this recombinant herpesvirus has no inherent advantage over AAV for delivery of potentially therapeutic monoclonal antibodies in a rhesus monkey model.

Original languageEnglish (US)
Pages (from-to)487-492
Number of pages6
JournalGene Therapy
Volume24
Issue number8
DOIs
StatePublished - Aug 1 2017

Fingerprint

Herpesviridae
Macaca mulatta
Rhadinovirus
Antibodies
Dependovirus
B-Lymphocytes
Monoclonal Antibodies
Antibody Formation
Haplorhini

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

Bischof, G. F., Shin, Y. C., Fuchs, S. P., Martinez-Navio, J. M., Lauer, W. A., Rakasz, E. G., & Desrosiers, R. C. (2017). Use of a gamma-2 herpesvirus as a vector to deliver antibodies to rhesus monkeys. Gene Therapy, 24(8), 487-492. https://doi.org/10.1038/gt.2017.49

Use of a gamma-2 herpesvirus as a vector to deliver antibodies to rhesus monkeys. / Bischof, G. F.; Shin, Y. C.; Fuchs, S. P.; Martinez-Navio, J. M.; Lauer, W. A.; Rakasz, E. G.; Desrosiers, Ronald Charles.

In: Gene Therapy, Vol. 24, No. 8, 01.08.2017, p. 487-492.

Research output: Contribution to journalArticle

Bischof, GF, Shin, YC, Fuchs, SP, Martinez-Navio, JM, Lauer, WA, Rakasz, EG & Desrosiers, RC 2017, 'Use of a gamma-2 herpesvirus as a vector to deliver antibodies to rhesus monkeys', Gene Therapy, vol. 24, no. 8, pp. 487-492. https://doi.org/10.1038/gt.2017.49
Bischof GF, Shin YC, Fuchs SP, Martinez-Navio JM, Lauer WA, Rakasz EG et al. Use of a gamma-2 herpesvirus as a vector to deliver antibodies to rhesus monkeys. Gene Therapy. 2017 Aug 1;24(8):487-492. https://doi.org/10.1038/gt.2017.49
Bischof, G. F. ; Shin, Y. C. ; Fuchs, S. P. ; Martinez-Navio, J. M. ; Lauer, W. A. ; Rakasz, E. G. ; Desrosiers, Ronald Charles. / Use of a gamma-2 herpesvirus as a vector to deliver antibodies to rhesus monkeys. In: Gene Therapy. 2017 ; Vol. 24, No. 8. pp. 487-492.
@article{3caed4605811472a897d2234f2b893a3,
title = "Use of a gamma-2 herpesvirus as a vector to deliver antibodies to rhesus monkeys",
abstract = "The gamma-2 herpesvirus of rhesus monkeys, rhesus monkey rhadinovirus (RRV), persists principally in B cells of its host. We constructed recombinant strains of RRV expressing the rhesus monkey-derived anti-SIV monoclonal antibodies 4L6 and 5L7 and compared the RRV-mediated in vivo delivery of these antibodies in rhesus monkeys with previous studies that utilized intramuscular delivery with an adeno-associated virus (AAV) vector. Recombinant RRV-4L6 and RRV-5L7 were both shown to stably produce the antibodies in persistently infected B-cell lines in culture. Two RRV-negative rhesus monkeys were experimentally infected with recombinant RRV-4L6 and two with recombinant RRV-5L7. Following infection, the appearance of the delivered antibody was readily detected in all four animals. However, the levels of the delivered antibody were considerably lower than what has been typically observed following intramuscular AAV delivery. Furthermore, three of the four monkeys had an antibody response to the delivered antibody as had been observed previously with intramuscular AAV delivery of these same antibodies. We conclude that this recombinant herpesvirus has no inherent advantage over AAV for delivery of potentially therapeutic monoclonal antibodies in a rhesus monkey model.",
author = "Bischof, {G. F.} and Shin, {Y. C.} and Fuchs, {S. P.} and Martinez-Navio, {J. M.} and Lauer, {W. A.} and Rakasz, {E. G.} and Desrosiers, {Ronald Charles}",
year = "2017",
month = "8",
day = "1",
doi = "10.1038/gt.2017.49",
language = "English (US)",
volume = "24",
pages = "487--492",
journal = "Gene Therapy",
issn = "0969-7128",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Use of a gamma-2 herpesvirus as a vector to deliver antibodies to rhesus monkeys

AU - Bischof, G. F.

AU - Shin, Y. C.

AU - Fuchs, S. P.

AU - Martinez-Navio, J. M.

AU - Lauer, W. A.

AU - Rakasz, E. G.

AU - Desrosiers, Ronald Charles

PY - 2017/8/1

Y1 - 2017/8/1

N2 - The gamma-2 herpesvirus of rhesus monkeys, rhesus monkey rhadinovirus (RRV), persists principally in B cells of its host. We constructed recombinant strains of RRV expressing the rhesus monkey-derived anti-SIV monoclonal antibodies 4L6 and 5L7 and compared the RRV-mediated in vivo delivery of these antibodies in rhesus monkeys with previous studies that utilized intramuscular delivery with an adeno-associated virus (AAV) vector. Recombinant RRV-4L6 and RRV-5L7 were both shown to stably produce the antibodies in persistently infected B-cell lines in culture. Two RRV-negative rhesus monkeys were experimentally infected with recombinant RRV-4L6 and two with recombinant RRV-5L7. Following infection, the appearance of the delivered antibody was readily detected in all four animals. However, the levels of the delivered antibody were considerably lower than what has been typically observed following intramuscular AAV delivery. Furthermore, three of the four monkeys had an antibody response to the delivered antibody as had been observed previously with intramuscular AAV delivery of these same antibodies. We conclude that this recombinant herpesvirus has no inherent advantage over AAV for delivery of potentially therapeutic monoclonal antibodies in a rhesus monkey model.

AB - The gamma-2 herpesvirus of rhesus monkeys, rhesus monkey rhadinovirus (RRV), persists principally in B cells of its host. We constructed recombinant strains of RRV expressing the rhesus monkey-derived anti-SIV monoclonal antibodies 4L6 and 5L7 and compared the RRV-mediated in vivo delivery of these antibodies in rhesus monkeys with previous studies that utilized intramuscular delivery with an adeno-associated virus (AAV) vector. Recombinant RRV-4L6 and RRV-5L7 were both shown to stably produce the antibodies in persistently infected B-cell lines in culture. Two RRV-negative rhesus monkeys were experimentally infected with recombinant RRV-4L6 and two with recombinant RRV-5L7. Following infection, the appearance of the delivered antibody was readily detected in all four animals. However, the levels of the delivered antibody were considerably lower than what has been typically observed following intramuscular AAV delivery. Furthermore, three of the four monkeys had an antibody response to the delivered antibody as had been observed previously with intramuscular AAV delivery of these same antibodies. We conclude that this recombinant herpesvirus has no inherent advantage over AAV for delivery of potentially therapeutic monoclonal antibodies in a rhesus monkey model.

UR - http://www.scopus.com/inward/record.url?scp=85030766232&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030766232&partnerID=8YFLogxK

U2 - 10.1038/gt.2017.49

DO - 10.1038/gt.2017.49

M3 - Article

VL - 24

SP - 487

EP - 492

JO - Gene Therapy

JF - Gene Therapy

SN - 0969-7128

IS - 8

ER -